Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: J Allergy Clin Immunol. 2021 Mar 10;147(6):2271–2280.e8. doi: 10.1016/j.jaci.2021.02.038

Figure 1:

Figure 1:

Study design. Depicted days indicate visits with laboratory studies. Black arrows indicate days of omalizumab dosing. Blue arrows indicate timing of skin biopsies. The second skin biopsy occurred between day 6 and 30 at the time of 50% symptom reduction relative to baseline UAS-7. If 50% symptom reduction was not achieved by day 30 then biopsy performed at day 30.